Summary
Leonardo Faoro is a physician–drug developer with over 15 years leading oncology clinical programs across phases I–IV and multiple IND and BLA/NDA interactions. Currently serving as Chief Medical Officer, he has built inaugural clinical organizations and steered cross-functional teams to file three INDs for KRAS inhibitors, while previously directing Exelixis’ early clinical portfolio including ADCs and CDK7 inhibitors. He blends deep clinical trial execution with strategic portfolio and BD collaboration, frequently interfacing with regulators, boards, and investors. Trained in medical oncology with an MBA from UC Berkeley/Columbia, he pairs frontline patient-centered research experience with commercial and deal-making acumen. An uncommonly pragmatic clinician-scientist, he also experiments with AI and creative side projects, describing himself as an “AI create as I speak” dilettante.
10 years of coding experience
4 years of employment as a software developer
MBA, MBA at University of California, Berkeley, Haas School of Business
MD Medicine, MD Medicine at Universidade Federal do Paraná
Fellowship in Medical Oncology, Fellowship in Medical Oncology at University of Chicago
MBA, MBA at Columbia Business School
Internal Medicine Residency, Internal Medicine Residency at Mayo Clinic